Genedata, a leading provider of advanced software solutions for drug discovery and life science research, has announced Genedata Biologics™ will be featured at the Fourth Annual PEGS Europe Protein & Antibody Engineering Summit. A first-in-class, end-to-end solution for biologics R&D, Genedata Biologics will be showcased at the PEGS session on "Enhancing Expression and Achieving Higher Throughput." The session will detail UCB Pharma's novel data management and workflow system based on Genedata Biologics and optimized for automation of high-throughput processes spanning molecular biology, expression, purification, and analytics. Co-presented by UCB Pharma and Genedata, the session will be held on November 7 (PEGS Europe Nov 6-8).
Recent advances in cell line development and automation technologies enable the parallel expression of large numbers of biomolecules. The collection, management, and interpretation of biologics data can be a time-consuming process that impedes efficient discovery and development of protein-based drugs. As an end-to-end data management system, Genedata Biologics addresses these inefficiencies. Collaborating with Genedata, UCB Pharma has further enhanced the Genedata Biologics system. Capabilities, which will be examined at PEGS, include:
-Comprehensive workflow support and knowledge management for antibody discovery
-Large-scale molecule generation via novel bulk in silico cloning tools
-Sophisticated biologics molecule and sample management (e.g. material genealogy)
-Integrated system for biotherapeutics and tool proteins (reagents)
-Centralized data access for scientists across different sites and groups
-Integration with corporate IT systems (i.e. humanization applications, ELN, etc.)
"We are continually innovating Genedata Biologics to support scientists in their daily research," said Dr. Othmar Pfannes. "Our work with UCB underscores that innovation, which extends Genedata Biologics' value beyond data management with enriched support for complex workflows, new technologies, and logistics."